Secondary analysis of two pooled phase 3 trials in females with uncomplicated UTI: therapeutic success favoured gepotidacin over nitrofurantoin by 9.6% (susceptible) and 20.8% (non-susceptible uropathogens); clinical success gaps non-significant.
Secondary analysis
Sheets et al. Subgroup Analysis of Pooled Phase 3 Efficacy Data From Two Randomized Trials of Gepotidacin Versus Nitrofurantoin in Uncomplicated Urinary Tract Infections (EAGLE-2 and EAGLE-3) Including Participants With Uropathogens Not-Susceptible to Nitrofurantoin